Oncolytic virus trial for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 80 years old
- Have a diagnosis of locally advanced esophageal squamous cell carcinoma, with or without neck lymph node spread
- Able to provide a fresh tumor sample before treatment
- Have good organ function and an activity level of 0 or 1 on a standard scale
- Not have had chemotherapy, radiation, or immunotherapy for a different first-line treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a virus-based gene therapy injected directly into tumors with an immunotherapy drug. It aims to help people with advanced head and neck or esophageal cancer who have already tried other treatments.
This trial tests a personalized vaccine made from your tumor's unique markers (neoantigens) to help prevent your advanced esophageal cancer from coming back. It's for people who have already completed strong treatment and are currently cancer-free, but have a high risk of recurrence.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.